BioCentury
ARTICLE | Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

November 27, 2018 11:26 PM UTC

G1 Therapeutics Inc. (NASDAQ:GTHX) shares fell $4.54 (11%) to $35.39 Tuesday after Phase II data showed that the company’s trilaciclib plus Tecentriq atezolizumab and chemotherapy failed to show an improvement in overall response rate (ORR) to treat small cell lung cancer.

The agent did provide myeloprotective benefits, however, and ORR is known to be a poor indicator of benefit for immunotherapy combinations -- even anti-PD-L1 mAb Tecentriq showed no improvement in ORR and went onto to have an overall survival (OS) benefit in this same indication (see "Rethinking RECIST for Immunotherapies" & "Genentech's Immunotherapy Improves Survival by Two Months in First-line SCLC"). ...